Composition and method for treating neurological disease
AssigneeOsmotica Kereskedelmi és Szolgáltató Korlátolt Felelõsségû Társaság
InventorsGlenn A. Meyer, Joaquina Faour, Ana Cristina Pastini, Marcelo Fernando Befumo
Life of this patent
Estimating the term…
Abstract
The present disclosure is directed to methods of treating neurological disorders in a patient such as Parkinson's disease, drug-induced extrapyramidal reactions, and/or levodopa-induced dyskinesia comprising administering to the patient once daily in the morning a pharmaceutical composition comprising about 50 mg to about 400 mg of extended-release amantadine or a pharmaceutically acceptable salt thereof.
Claims23
A method of treating Parkinson's disease in a patient, comprising administering to the patient a pharmaceutical composition comprising i) an osmotic agent and amantadine or a pharmaceutically acceptable salt thereof in an extended release form, and ii) amantadine or a pharmaceutically acceptable salt thereof in an immediate release form, wherein the composition comprises 258 mg of amantadine free base equivalent, and wherein the mean steady-state Cavg of the composition is at least 95% of the mean steady-state Cavg provided by the same daily quantity of amantadine or a pharmaceutically acceptable salt thereof in an immediate release form.
A method of treating Parkinson's disease in a patient, comprising administering to the patient a pharmaceutical composition comprising i) an osmotic agent and amantadine or a pharmaceutically acceptable salt thereof in an extended release form, and ii) amantadine or a pharmaceutically acceptable salt thereof in an immediate release form, wherein the composition comprises 258 mg of amantadine free base equivalent, and wherein the steady-state AUC0-24 for the composition is at least 95% of the steady-state AUC0-24 provided by the same daily quantity of amantadine or a pharmaceutically acceptable salt thereof in an immediate release form.
A method of treating Parkinson's disease in a patient, comprising administering to the patient a pharmaceutical composition comprising i) an osmotic agent and amantadine or a pharmaceutically acceptable salt thereof in an extended release form, and ii) amantadine or a pharmaceutically acceptable salt thereof in an immediate release form, wherein the composition comprises 258 mg of amantadine free base equivalent, and wherein the steady-state Cmax of the composition is comparable to the steady-state Cmax provided by the same daily quantity of amantadine or a pharmaceutically acceptable salt thereof in an immediate release form.
A method of treating Parkinson's disease in a patient, comprising administering to the patient a pharmaceutical composition comprising i) an osmotic agent and amantadine or a pharmaceutically acceptable salt thereof in an extended release form, and ii) amantadine or a pharmaceutically acceptable salt thereof in an immediate release form, wherein the composition comprises 258 mg of amantadine free base equivalent, and wherein steady-state is achieved by about Day 6.
Dependencies are inferred from the claim text.